Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5068 - First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Karim Amrane


Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260


K. Amrane1, M. Geier1, R. Corre2, G. Léveiller3, G. Florence4, R. Lamy5, J.L. Bizec6, E. Goarant7, G. Robinet1, S. Ulrike8, G. Quere1, C. Bernier9, R. Descourt1

Author affiliations

  • 1 Department Of Oncology, C.H.U. Brest - Hôpital Morvan, 29609 - Brest/FR
  • 2 Department Of Pulmonary Diseases, CHU de Pontchaillou, 35033 - Rennes/FR
  • 3 Department Of Pulmonary Diseases, CH Yves le Foll, 22000 - Saint Brieuc/FR
  • 4 Department Of Pulmonary Diseases, CH Pays de Morlaix, 29600 - Morlaix/FR
  • 5 Department Of Oncology, CH Bretagne Sud, 56322 - Lorient/FR
  • 6 Department Of Pulmonary Diseases, CH Bretagne-Atlantique, 56017 - Vannes/FR
  • 7 Department Of Pulmonary Diseases, Hospital of Saint-Malo, 35400 - Saint Malo/FR
  • 8 Department Of Radiotherapy, C.H.U. Brest - Hôpital Morvan, 29609 - Brest/FR
  • 9 Department Of Pulmonary Diseases, CH Rene Pleven, 22100 - Dinan/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5068


Pembrolizumab significantly improves progression-free survival (PFS) (median 10.3 months) and overall survival (OS) (median 30.0 months) in selected patients with previously untreated advanced non–small-cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS) ≥ 50% and without EGFR/ALK aberrations. Data in real life conditions are missing.


This was a cross-sectional, retrospective study of untreated advanced NSCLC patients with TPS ≥ 50% and without EGFR/ALK aberrations, from 9 French hospitals in Brittany area. The study included 115 patients and analysis focused on 108 patients. At index, the main characteristics of our cohort were: median age [range] 66.7 [37 to 87] years, 71 % male, 23.1 % performans status (P.S) 2, 88.8 % current or former smokers. 87.1 % had Stage IV at diagnosis and 9.2 % had untreated brain metastasis. 23.4% had mutations (KRAS, MET, BRAF and ROS 1). We used Kaplan-Meier analysis for PFS and described tolerability.


With a median follow-up of 7.1 months, median PFS was 10.1 months (95% confidence interval [CI], 8.8 to 11.4), (range, and 0.6 to 18.5 months). The objective response rate was 58,2% (complete response: 2.7 % and partial response: 55.5 %). Disease control rate was 72.1%. The estimated rate of OS at 6 months was 86.6 %. Treatment-related adverse events of grade 3 (AE) occurred in 7.4% of patients. There was no grade 4 or 5 AE and mean time between first administration of pembrolizumab and clinico-biological AE was 13.9 (± 9.7) weeks. Our data are immature to appreciate OS.


In a real life cohort of patients (PS 2, untreated brain metastasis), with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab demonstrates similar PFS with KEYNOTE-024 phase III trial.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Renaud Descourt.


Association Bretonne de Cancérologie Thoracique (ABCT).


R. Corre: Travel / Accommodation / Expenses, Officer / Board of Directors: bms. G. Robinet: Advisory / Consultancy: MSD; Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): BMS; Research grant / Funding (institution): Roche. R. Descourt: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: takeda; Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy: Novartis; Advisory / Consultancy: BMS; Travel / Accommodation / Expenses: Pfizer. All other authors have declared no conflicts of interest. Linguistic correction

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.